Find Funding Opportunities

This Funding Opportunity Announcement solicits research applications that propose implementation science methodology to embed existing evidence-based coordinated pain care models into a variety of public and private health care systems (HCS) where this type of care does not exist. Applications that combine comparative effectiveness studies of innovative coordinated care models with strong implementation science methodology to embed effective approaches into HCSs also are encouraged. This NOFO requires that the coordinated care model under study be embedded into the health care delivery system of the applicant institutions. Coordinated pain care approaches proposed for study should include interventions from multiple disciplines as described below and should aim to improve pain management based on the biopsychosocial model of pain. Emphasis should be on populations of patients with greatest need. This NOFO solicits applications from HCS who have resources and infrastructure to support research and implementation of study approaches in partnership with those HCS who lack research resources or experience and would benefit most from implementation of cost-effective coordinated pain care. HCS partners who serve populations that are under-represented in research are encouraged to apply. Models of coordinated care proposed by the study team should be aligned with health care resources of the participating HCS and should be informed through engagement of stakeholders including patients, providers, healthcare system executives, policy makers, and payors. The study teams must include health care providers from multiple disciplines and implementation scientists.

This is a non-competitive funding opportunity intended to fund a single award. The National Institute of Neurological Disorders and Stroke is announcing its intent to issue a single source cooperative agreementto the Hennepin Healthcare Research Institute to submit a renewal application to complete the phase II Hyperbaric Oxygen Brain Injury Treatment (HOBIT) clinical trial.

This RFA is soliciting applications proposing placebo-controlled, clinical trials to determine the efficacy and safety of FDA approved monoclonal antibody therapies directed against amyloid compared to placebo in diverse "mixed dementia" populations with a focus on Lewy Body Dementias (LBD). In this NOFO the mixed-etiology dementias (MED) that are of interest and that are in scope are cognitive impairment and dementia cases positive for 1) canonical Alzheimers pathology biomarkers (for example, amyloid deposition assessed using positron emission tomography and/or low cerebrospinal fluid amyloid beta 42 combined with elevated phosphorylated tau; and 2) a clinical LBD diagnosis, i.e. Parkinsons disease dementia (PDD) and/or dementia with Lewy bodies (DLB). Bayesian approaches with response adaptive randomization to examine specific subgroups are encouraged. Successful applications will be powered to determine efficacy in diverse populations representative of the distribution of the disease in the United States by sex, race/ethnicity, and geographic distribution. Applications must include elements of patient and community engagement that are incorporated into all stages of program development and at all levels of the organizational structure.

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional)

The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutionsis to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F and A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. See Part II. Section 3.1 Eligible Organizations for more information.

The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F and A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. This Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. For the purpose of this NOFO, minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.

This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.

The purpose of this notice of funding opportunity (NOFO) is to support research that 1) defines associations between variations in human leukocyte antigen (HLA) and killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, 2) elucidates mechanisms underlying these associations with the goal of advancing therapeutic opportunities, and/or 3) validates association data in order to improve the predictive power of clinical disease screening.

This NOFO will solicit R01 applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates AD/ADRD-relevant phenotypes. Either the model itself or the experimental readouts will be required to incorporate AD/ADRD risk factors, pathologies, or relevant comorbidities. To this end, proposals can focus on one or more of the following: - Mechanistic studies that address how COVID-19 impacts CNS pathology and cognitive outcomes when AD/ADRD pathology is already present (for example, in a model of AD/ADRD). - Mechanistic studies that address how COVID-19 accelerates AD/ADRD pathology and cognitive deficits in a prodromal model (early phase, pre-symptomatic). - Mechanistic studies that address how COVID-19 predisposes for AD/ADRD and/or interacts with relevant comorbid conditions and risk factors (cellular mechanisms that could potentially increase the risk for future AD/ADRD).

This initiative is designed to promote discovery of cellular and molecular mechanisms that underlie brain blood vessels responses to passive anti-beta-amyloid immunotherapy that result in amyloid-related imaging abnormalities (ARIA). The goal is to establish an understanding of molecular mechanisms that can be targeted to protect the blood brain barrier (BBB), and thus the brain blood vessels, during therapeutic interventions that target beta-amyloid.